BeiGene Analyst Ratings
J.P. Morgan Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $200
TD Cowen Initiates BeiGene(BGNE.US) With Buy Rating, Announces Target Price $254
TD Cowen Sticks to Its Buy Rating for BeiGene (BGNE)
Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $284
Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $284
Jefferies Sticks to Their Buy Rating for BeiGene (BGNE)
BofA Securities Maintains BeiGene(BGNE.US) With Hold Rating, Raises Target Price to $198
Hold Rating on BeiGene Amid Mixed Drug Performance and Strong Pipeline Potential
BeiGene's Strong Financial and Clinical Prospects Solidify Buy Rating
BeiGene Analyst Ratings
BeiGene's Brukinsa Drives Strong Growth and Justifies Buy Rating
Buy Rating for BeiGene Backed by Brukinsa's Market Growth and Strong Financial Outlook
Nomura Adjusts BeiGene's Price Target to HK$158.37 From HK$150, Keeps at Buy
B of A Securities Maintains Neutral on BeiGene, Lowers Price Target to $152.5
BeiGene Analyst Ratings
BeiGene Analysis: Hold Rating Amidst Mixed Drug Sales Performance and Market Competition
BeiGene Performance Analysis: A Hold Rating With Cautious Optimism Amidst Competitive Pressures
BeiGene's Soaring Sales and Path to Profitability Reinforce Buy Rating
Buy Rating Affirmed for BeiGene on Strong Q4 Performance and Promising Brukinsa Sales